These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21626051)

  • 1. A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
    Infante JR; Jones SF; Bendell JC; Greco FA; Yardley DA; Lane CM; Spigel DR; Hainsworth JD; Burris HA
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):137-44. PubMed ID: 21626051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
    Awada A; Gil T; Whenham N; Van Hamme J; Besse-Hammer T; Brendel E; Delesen H; Joosten MC; Lathia CD; Loembé BA; Piccart-Ghebart M; Hendlisz A
    J Clin Pharmacol; 2011 Dec; 51(12):1674-84. PubMed ID: 21209247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
    Saif MW; Lansigan F; Ruta S; Lamb L; Mezes M; Elligers K; Grant N; Jiang ZL; Liu SH; Cheng YC
    Phytomedicine; 2010 Mar; 17(3-4):161-9. PubMed ID: 20092990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.
    Shacham-Shmueli E; Geva R; Figer A; Bulocinic S; Nalbandyan K; Shpigel S; Atsmon J; Brendel E
    J Clin Pharmacol; 2012 May; 52(5):656-69. PubMed ID: 22232731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
    Baselga J; Segalla JG; Roché H; Del Giglio A; Pinczowski H; Ciruelos EM; Filho SC; Gómez P; Van Eyll B; Bermejo B; Llombart A; Garicochea B; Durán MÁ; Hoff PM; Espié M; de Moraes AA; Ribeiro RA; Mathias C; Gil Gil M; Ojeda B; Morales J; Kwon Ro S; Li S; Costa F
    J Clin Oncol; 2012 May; 30(13):1484-91. PubMed ID: 22412143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
    Awada A; Hendlisz A; Christensen O; Lathia CD; Bartholomeus S; Lebrun F; de Valeriola D; Brendel E; Radtke M; Delaunoit T; Piccart-Gebhart M; Gil T
    Eur J Cancer; 2012 Mar; 48(4):465-74. PubMed ID: 22285181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
    Mardjuadi F; Medioni J; Kerger J; D'Hondt L; Canon JL; Duck L; Musuamba F; Oudard S; Clausse M; Moxhon A; Machiels JP
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):293-303. PubMed ID: 22752248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
    Campone M; Isambert N; Bourbouloux E; Roché H; Bonneterre J; Milano G; Fumoleau P
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):871-9. PubMed ID: 22045498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
    Farid M; Chowbay B; Chen X; Tan SH; Ramasamy S; Koo WH; Toh HC; Choo SP; Ong SY
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):141-50. PubMed ID: 22648745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors.
    Michaelson MD; Ryan DP; Fuchs CS; Supko JG; Garcia-Carbonero R; Paul Eder J; Clark JW
    Cancer; 2003 Jan; 97(1):148-54. PubMed ID: 12491516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase one dose finding study of capecitabine (Xeloda), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer.
    Stokes Z; Symonds P; Habeshaw T; Reed N; Curto J; Joynson C; Chan S
    Gynecol Oncol; 2005 Jun; 97(3):790-5. PubMed ID: 15894361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors.
    Fakih MG; Creaven PJ; Ramnath N; Trump D; Javle M; Strychor S; Repinski TV; Zamboni BA; Schwarz JK; French RA; Zamboni WC
    Clin Cancer Res; 2005 Aug; 11(16):5942-9. PubMed ID: 16115937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
    Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
    Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
    Saif MW; Sarantopoulos J; Patnaik A; Tolcher AW; Takimoto C; Beeram M
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1565-73. PubMed ID: 21547572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma.
    Petrini I; Lencioni M; Ricasoli M; Iannopollo M; Orlandini C; Oliveri F; Bartolozzi C; Ricci S
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):773-80. PubMed ID: 22033636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer.
    Traina TA; Theodoulou M; Feigin K; Patil S; Tan KL; Edwards C; Dugan U; Norton L; Hudis C
    J Clin Oncol; 2008 Apr; 26(11):1797-802. PubMed ID: 18398145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
    Camidge DR; Gail Eckhardt S; Gore L; O'Bryant CL; Leong S; Basche M; Holden SN; Musib L; Baldwin J; Darstein C; Thornton D; Finn RS; Britten CD
    Anticancer Drugs; 2008 Jan; 19(1):77-84. PubMed ID: 18043132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
    Cohen SJ; Engstrom PF; Lewis NL; Langer CJ; McLaughlin S; Beard M; Weiner LM; Meropol NJ
    Am J Clin Oncol; 2008 Feb; 31(1):1-5. PubMed ID: 18376220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
    Pronk LC; Vasey P; Sparreboom A; Reigner B; Planting AS; Gordon RJ; Osterwalder B; Verweij J; Twelves C
    Br J Cancer; 2000 Jul; 83(1):22-9. PubMed ID: 10883663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.